{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:47:10Z","timestamp":1790621230527,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1038\/ncpneuro0199","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T04:59:11Z","timestamp":1148446751000},"page":"330-338","source":"Crossref","is-referenced-by-count":123,"title":["Mechanisms of Disease: histone modifications in Huntington's disease"],"prefix":"10.1038","volume":"2","author":[{"given":"Ghazaleh","family":"Sadri-Vakili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Ho J","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpneuro0199_CR1","volume-title":"Huntington's Disease","author":"G Bates","year":"2002","unstructured":"Bates G et al. (Eds; 2002) Huntington's Disease. New York: Oxford University Press"},{"key":"BFncpneuro0199_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","volume":"57","author":"JP Vonsattel","year":"1998","unstructured":"Vonsattel JP and DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57: 369\u2013384","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFncpneuro0199_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/321168a0","volume":"321","author":"MF Beal","year":"1986","unstructured":"Beal MF et al. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321: 168\u2013171","journal-title":"Nature"},{"key":"BFncpneuro0199_CR4","doi-asserted-by":"crossref","unstructured":"Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is unstable in Huntington's disease chromosomes. Cell 72: 971\u2013983","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"BFncpneuro0199_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"MP Duyao","year":"1993","unstructured":"Duyao MP et al. (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387\u2013392","journal-title":"Nat Genet"},{"key":"BFncpneuro0199_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.ne.19.030196.000455","volume":"19","author":"HL Paulson","year":"1996","unstructured":"Paulson HL and Fischbeck KH (1996) Trinucleotide repeats in neurogenetic disorders. Annu Rev Neurosci 19: 79\u2013107","journal-title":"Annu Rev Neurosci"},{"key":"BFncpneuro0199_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/0166-2236(90)90111-M","volume":"13","author":"M DiFiglia","year":"1990","unstructured":"DiFiglia M (1990) Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13: 286\u2013289","journal-title":"Trends Neurosci"},{"key":"BFncpneuro0199_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0005-2728(98)00114-5","volume":"1366","author":"MF Beal","year":"1998","unstructured":"Beal MF (1998) Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta Bio Energetics 1366: 211\u2013223","journal-title":"Biochim Biophys Acta Bio Energetics"},{"key":"BFncpneuro0199_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/20446","volume":"399","author":"VO Ona","year":"1999","unstructured":"Ona VO et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399: 263\u2013267","journal-title":"Nature"},{"key":"BFncpneuro0199_CR10","doi-asserted-by":"publisher","first-page":"9158","DOI":"10.1074\/jbc.273.15.9158","volume":"273","author":"CL Wellington","year":"1998","unstructured":"Wellington CL et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158\u20139167","journal-title":"J Biol Chem"},{"key":"BFncpneuro0199_CR11","doi-asserted-by":"publisher","first-page":"39594","DOI":"10.1074\/jbc.C200353200","volume":"277","author":"D Goffredo","year":"2002","unstructured":"Goffredo D et al. (2002) Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons. J Biol Chem 277: 39594\u201339598","journal-title":"J Biol Chem"},{"key":"BFncpneuro0199_CR12","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1093\/hmg\/ddg346","volume":"12","author":"ZH Qin","year":"2003","unstructured":"Qin ZH et al. (2003) Autophagy regulates the processing of amino terminal huntingtin fragments. Hum Mol Genet 12: 3231\u20133244","journal-title":"Hum Mol Genet"},{"key":"BFncpneuro0199_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36: 585\u2013595","journal-title":"Nat Genet"},{"key":"BFncpneuro0199_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","volume":"292","author":"NF Bence","year":"2001","unstructured":"Bence NF et al. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552\u20131555","journal-title":"Science"},{"key":"BFncpneuro0199_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S1097-2765(04)00151-0","volume":"14","author":"P Venkatraman","year":"2004","unstructured":"Venkatraman P et al. (2004) Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14: 95\u2013104","journal-title":"Mol Cell"},{"key":"BFncpneuro0199_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1097-2765(02)00602-0","volume":"10","author":"A Lunkes","year":"2002","unstructured":"Lunkes A et al. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10: 259\u2013269","journal-title":"Mol Cell"},{"key":"BFncpneuro0199_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","volume":"90","author":"SW Davies","year":"1997","unstructured":"Davies SW et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537\u2013548","journal-title":"Cell"},{"key":"BFncpneuro0199_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.0237018100","volume":"100","author":"CA Ross","year":"2003","unstructured":"Ross CA et al. (2003) Polyglutamine fibrillogenesis: the pathway unfolds. Proc Natl Acad Sci USA 100: 1\u20133","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR19","doi-asserted-by":"publisher","first-page":"17616","DOI":"10.1073\/pnas.0408134101","volume":"101","author":"DW Colby","year":"2004","unstructured":"Colby DW et al. (2004) Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 101: 17616\u201317621","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1126\/science.1124514","volume":"311","author":"T Gidalevitz","year":"2006","unstructured":"Gidalevitz T et al. (2006) Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311: 1471\u20131474","journal-title":"Science"},{"key":"BFncpneuro0199_CR21","doi-asserted-by":"publisher","first-page":"7268","DOI":"10.1523\/JNEUROSCI.20-19-07268.2000","volume":"20","author":"KB Kegel","year":"2000","unstructured":"Kegel KB et al. (2000) Huntingtin expression stimulates endosomal\u2013lysosomal activity, endosome tubulation, and autophagy. J Neurosci 20: 7268\u20137278","journal-title":"J Neurosci"},{"key":"BFncpneuro0199_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","volume":"23","author":"J-HJ Cha","year":"2000","unstructured":"Cha J-HJ (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23: 387\u2013392","journal-title":"Trends Neurosci"},{"key":"BFncpneuro0199_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","volume":"19","author":"KL Sugars","year":"2003","unstructured":"Sugars KL and Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19: 233\u2013238","journal-title":"Trends Genet"},{"key":"BFncpneuro0199_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S1566-2772(03)00059-8","volume":"3","author":"R Luthi-Carter","year":"2003","unstructured":"Luthi-Carter R and Cha J-H J (2003) Mechanisms of transcriptional dysregulation in Huntington's disease. Clin Neurosci Res 3: 165\u2013177","journal-title":"Clin Neurosci Res"},{"key":"BFncpneuro0199_CR25","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1126\/science.8303297","volume":"263","author":"H-P Gerber","year":"1994","unstructured":"Gerber H-P et al. (1994) Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263: 808\u2013811","journal-title":"Science"},{"key":"BFncpneuro0199_CR26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1073\/pnas.93.4.1560","volume":"93","author":"S Karlin","year":"1996","unstructured":"Karlin S and Burge C (1996) Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development. Proc Natl Acad Sci USA 93: 1560\u20131565","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR27","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1073\/pnas.100110097","volume":"97","author":"JS Steffan","year":"2000","unstructured":"Steffan JS et al. (2000) The Huntington's disease protein interacts with p53 and CBP and represses transcription. Proc Natl Acad Sci USA 97: 6763\u20136768","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR28","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1126\/science.1056784","volume":"291","author":"FC Nucifora Jr","year":"2001","unstructured":"Nucifora FC Jr et al. (2001) Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Science 291: 2423\u20132428","journal-title":"Science"},{"key":"BFncpneuro0199_CR29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/B:SCAM.0000007124.19463.e5","volume":"24","author":"CC Huang","year":"1998","unstructured":"Huang CC et al. (1998) Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat Cell Mol Genet 24: 217\u2013233","journal-title":"Somat Cell Mol Genet"},{"key":"BFncpneuro0199_CR30","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1126\/science.1072613","volume":"296","author":"AW Dunah","year":"2002","unstructured":"Dunah AW et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296: 2238\u20132243","journal-title":"Science"},{"key":"BFncpneuro0199_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ana.410420213","volume":"42","author":"SJ Augood","year":"1997","unstructured":"Augood SJ et al. (1997) Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann Neurol 42: 215\u2013221","journal-title":"Ann Neurol"},{"key":"BFncpneuro0199_CR32","doi-asserted-by":"publisher","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","volume":"95","author":"J-HJ Cha","year":"1998","unstructured":"Cha J-HJ et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci USA 95: 6480\u20136485","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR33","first-page":"276","volume-title":"In Huntington's Disease","author":"GJ Yohrling","year":"2002","unstructured":"Yohrling GJ and Cha J-HJ (2002) Neurochemistry of Huntington's Disease. In Huntington's Disease, 276\u2013308 (Eds Bates GP et al.) London: Oxford Medical Publications"},{"key":"BFncpneuro0199_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493\u2013506","journal-title":"Cell"},{"key":"BFncpneuro0199_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ana.410400110","volume":"40","author":"RA Weeks","year":"1996","unstructured":"Weeks RA et al. (1996) Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol 40: 49\u201354","journal-title":"Ann Neurol"},{"key":"BFncpneuro0199_CR36","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0306-4522(00)00008-7","volume":"97","author":"M Glass","year":"2000","unstructured":"Glass M et al. (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 97: 505\u2013519","journal-title":"Neuroscience"},{"key":"BFncpneuro0199_CR37","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/hmg\/9.9.1259","volume":"9","author":"R Luthi-Carter","year":"2000","unstructured":"Luthi-Carter R et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9: 1259\u20131271","journal-title":"Hum Mol Genet"},{"key":"BFncpneuro0199_CR38","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1073\/pnas.120166397","volume":"97","author":"JA Bibb","year":"2000","unstructured":"Bibb JA et al. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci USA 97: 6809\u20136814","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR39","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1111\/j.1460-9568.2004.03796.x","volume":"20","author":"H Hu","year":"2004","unstructured":"Hu H et al. (2004) Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20: 3351\u20133363","journal-title":"Eur J Neurosci"},{"key":"BFncpneuro0199_CR40","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1111\/j.1432-1033.2004.04460.x","volume":"271","author":"EA McCaw","year":"2004","unstructured":"McCaw EA et al. (2004) Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271: 4909\u20134920","journal-title":"Eur J Biochem"},{"key":"BFncpneuro0199_CR41","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/hmg\/11.17.1927","volume":"11","author":"R Luthi-Carter","year":"2002","unstructured":"Luthi-Carter R et al. (2002) Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet 11: 1927\u20131937","journal-title":"Hum Mol Genet"},{"key":"BFncpneuro0199_CR42","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1093\/hmg\/11.17.1939","volume":"11","author":"EYW Chan","year":"2002","unstructured":"Chan EYW et al. (2002) Increased huntingin protein length reduces the severity of polyglutamine-induced gene expression changes in mouse models of Huntington disease. Hum Mol Genet 11: 1939\u20131951","journal-title":"Hum Mol Genet"},{"key":"BFncpneuro0199_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2004.06.029","volume":"15","author":"G Schaffar","year":"2004","unstructured":"Schaffar G et al. (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell 15: 95\u2013105","journal-title":"Mol Cell"},{"key":"BFncpneuro0199_CR44","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.cell.2005.10.030","volume":"123","author":"W Zhai","year":"2005","unstructured":"Zhai W et al. (2005) In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 123: 1241\u20131253","journal-title":"Cell"},{"key":"BFncpneuro0199_CR45","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1073\/pnas.0503505102","volume":"102","author":"VB Palhan","year":"2005","unstructured":"Palhan VB et al. (2005) Polyglutamine-expanded ataxin-7 inhibits STAGA histone acetyltransferase activity to produce retinal degeneration. Proc Natl Acad Sci USA 102: 8472\u20138477","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/47412","volume":"403","author":"BD Strahl","year":"2000","unstructured":"Strahl BD and Allis CD (2000) The language of covalent histone modifications. Nature 403: 41\u201345","journal-title":"Nature"},{"key":"BFncpneuro0199_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","volume":"13","author":"PA Marks","year":"2001","unstructured":"Marks PA et al. (2001) Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477\u2013483","journal-title":"Curr Opin Oncol"},{"key":"BFncpneuro0199_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/cbt.189","volume":"2","author":"PK Davis","year":"2003","unstructured":"Davis PK and Brackmann RK (2003) Chromatin remodeling and cancer. Cancer Biol Ther 2: 22\u201329","journal-title":"Cancer Biol Ther"},{"key":"BFncpneuro0199_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1749-6632.2003.tb05977.x","volume":"983","author":"W Yasui","year":"2003","unstructured":"Yasui W et al. (2003) Histone acetylation and gastrointestinal carcinogenesis. Ann NY Acad Sci 983: 220\u2013231","journal-title":"Ann NY Acad Sci"},{"key":"BFncpneuro0199_CR50","first-page":"962","volume":"7","author":"LM Butler","year":"2001","unstructured":"Butler LM et al. (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7: 962\u2013970","journal-title":"Clin Cancer Res"},{"key":"BFncpneuro0199_CR51","doi-asserted-by":"publisher","first-page":"10014","DOI":"10.1073\/pnas.180316197","volume":"97","author":"VM Richon","year":"2000","unstructured":"Richon VM et al. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97: 10014\u201310019","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","volume":"13","author":"DM Vigushin","year":"2002","unstructured":"Vigushin DM and Coombes RC (2002) Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13: 1\u201313","journal-title":"Anticancer Drugs"},{"key":"BFncpneuro0199_CR53","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1073\/pnas.261400698","volume":"98","author":"A McCampbell","year":"2001","unstructured":"McCampbell A et al. (2001) Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci USA 98: 15179\u201315184","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR54","doi-asserted-by":"publisher","first-page":"13201","DOI":"10.1073\/pnas.191498198","volume":"98","author":"RE Hughes","year":"2001","unstructured":"Hughes RE et al. (2001) Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci USA 98: 13201\u201313206","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/35099568","volume":"413","author":"JS Steffan","year":"2001","unstructured":"Steffan JS et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739\u2013743","journal-title":"Nature"},{"key":"BFncpneuro0199_CR56","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","volume":"23","author":"RJ Ferrante","year":"2003","unstructured":"Ferrante RJ et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23: 9418\u20139427","journal-title":"J Neurosci"},{"key":"BFncpneuro0199_CR57","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1073\/pnas.0437870100","volume":"100","author":"E Hockly","year":"2003","unstructured":"Hockly E et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 100: 2041\u20132046","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncpneuro0199_CR58","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1074\/jbc.M410210200","volume":"280","author":"G Gardian","year":"2005","unstructured":"Gardian G et al. (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280: 556\u2013563","journal-title":"J Biol Chem"},{"key":"BFncpneuro0199_CR59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","volume":"14","author":"S Igarashi","year":"2003","unstructured":"Igarashi S et al. (2003) Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14: 565\u2013568","journal-title":"Neuroreport"},{"key":"BFncpneuro0199_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0006-291X(02)00498-9","volume":"294","author":"N Hazeki","year":"2002","unstructured":"Hazeki N et al. (2002) Ultrastructure of nuclear aggregates formed by expressing an expanded polyglutamine. Biochem Biophys Res Commun 294: 429\u2013440","journal-title":"Biochem Biophys Res Commun"},{"key":"BFncpneuro0199_CR61","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/j.1471-4159.2005.03447.x","volume":"96","author":"H Ryu","year":"2006","unstructured":"Ryu H et al. (2006) Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 96: 908","journal-title":"J Neurochem"},{"key":"BFncpneuro0199_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1124\/mi.2.1.47","volume":"2","author":"E Costa","year":"2002","unstructured":"Costa E et al. (2002) REELIN and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interv 2: 47\u201357","journal-title":"Mol Interv"},{"key":"BFncpneuro0199_CR63","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/j.1471-4159.2004.02406.x","volume":"89","author":"M Ren","year":"2004","unstructured":"Ren M et al. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89: 1358\u20131367","journal-title":"J Neurochem"},{"key":"BFncpneuro0199_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ijc.20372","volume":"112","author":"A Villar-Garea","year":"2004","unstructured":"Villar-Garea A and Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112: 171\u2013178","journal-title":"Int J Cancer"},{"key":"BFncpneuro0199_CR65","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0006-291X(82)80067-3","volume":"108","author":"S Jahangeer","year":"1982","unstructured":"Jahangeer S et al. (1982) \u03b2-adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun 108: 1434\u20131440","journal-title":"Biochem Biophys Res Commun"},{"key":"BFncpneuro0199_CR66","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1471-4892(03)00084-5","volume":"3","author":"PA Marks","year":"2003","unstructured":"Marks PA et al. (2003) Histone deacetylases. Curr Opin Pharmacol 3: 344\u2013351","journal-title":"Curr Opin Pharmacol"},{"key":"BFncpneuro0199_CR67","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1038\/sj.onc.1206502","volume":"22","author":"HJ Shin","year":"2003","unstructured":"Shin HJ et al. (2003) Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22: 3853\u20133858","journal-title":"Oncogene"},{"key":"BFncpneuro0199_CR68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","volume":"84","author":"GJ Dover","year":"1994","unstructured":"Dover GJ et al. (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84: 339\u2013343","journal-title":"Blood"},{"key":"BFncpneuro0199_CR69","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","volume":"157","author":"RC Rubenstein","year":"1998","unstructured":"Rubenstein RC and Zeitlin PL (1998) A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in \u0394F508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157: 484\u2013490","journal-title":"Am J Respir Crit Care Med"},{"key":"BFncpneuro0199_CR70","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<221::AID-AJH4>3.0.CO;2-R","volume":"62","author":"C Hoppe","year":"1999","unstructured":"Hoppe C et al. (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 62: 221\u2013227","journal-title":"Am J Hematol"},{"key":"BFncpneuro0199_CR71","first-page":"3047","volume":"7","author":"MA Carducci","year":"2001","unstructured":"Carducci MA et al. (2001) A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7: 3047\u20133055","journal-title":"Clin Cancer Res"},{"key":"BFncpneuro0199_CR72","first-page":"2292","volume":"7","author":"J Gilbert","year":"2001","unstructured":"Gilbert J et al. (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7: 2292\u20132300","journal-title":"Clin Cancer Res"},{"key":"BFncpneuro0199_CR73","first-page":"3578","volume":"9","author":"WK Kelly","year":"2003","unstructured":"Kelly WK et al. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578\u20133588","journal-title":"Clin Cancer Res"}],"container-title":["Nature Clinical Practice Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0199","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpneuro0199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneuro0199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:26:18Z","timestamp":1684441578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneuro0199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["BFncpneuro0199"],"URL":"https:\/\/doi.org\/10.1038\/ncpneuro0199","relation":{},"ISSN":["1745-834X","1745-8358"],"issn-type":[{"value":"1745-834X","type":"print"},{"value":"1745-8358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}